 The present application proposes to test WE with the addition of in vivo exposure in the United States as an effective treatment for GAD. The present study involves the randomization of 60 adults with GAD to either 1 12-sessions of WE therapy or 2 a 12-week waitlist WL, before entering into therapy. The authors hypothesize that participants in the WE intervention will evidence greater reductions in anxiety symptom severity and measures of quality of life relative to individuals randomized to the WL. 